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SUMMARY
 
We have investigated constitutive and phytohaemagglutinin (PHA) 
 
+
 
 phorbol 12-myristate 13-acetate
(PMA)-induced gene expression of tumour necrosis factor (TNF)-
 
a
 
, interferon (IFN)-
 
g
 
, interleukin
(IL)-2, IL-3, IL-4, IL-10, IL-12 and granulocyte macrophage colony-stimulating factor (GM-CSF) in
peripheral blood mononuclear cells (PBMCs) of 10 patients with Takayasu’s arteritis (TA) and 10
healthy controls by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR). The
constitutive mRNA expression of TNF-
 
a
 
 (69·0 
 
±
 
 4·0% 
 
versus
 
 27·5 
 
±
 
 18·0%; 
 
P
 
 
 
=
 
 0·001) and IL-4
(60·0 
 
±
 
 10·0% 
 
versus
 
 0%; 
 
P
 
 
 
=
 
 0·001) was significantly higher in patients than controls; that of IL-3 was
comparable in both groups (38·0 
 
±
 
 6·0% 
 
versus
 
 32·0 
 
±
 
 5·0%; 
 
P
 
 
 
=
 
 0·651) while no constitutive mRNA
expression was observed for the other cytokines studied. The stimulated PBMCs of patients, as
compared  with  the  controls,  had  higher  mRNA  gene  expression  of  TNF-
 
a
 
 (127·0 
 
±
 
 16·0%  
 
ver-
sus
 
 54·0 
 
±
 
 6·0%; 
 
P
 
 
 
=
 
 0·001), IFN-
 
g
 
 (93·0 
 
±
 
 13·0% 
 
versus
 
 57·0 
 
±
 
 5·0%; 
 
P
 
 
 
=
 
 0·032), IL-2 (109·0 
 
±
 
 13·0%
 
versus
 
 68·0 
 
±
 
 6·0%; 
 
P
 
 
 
=
 
 0·015), IL-3 (60·0 
 
±
 
 8·0% 
 
versus
 
 21·2 
 
±
 
 3·0%; 
 
P
 
 
 
=
 
 0·045) and IL-4 (68·0 
 
±
 
 7·0%
 
versus
 
 27·0 
 
±
 
 7·2%; 
 
P
 
 = 0·01) The mRNA expression of IL-10 was lower in patients than controls
(35·0 
 
±
 
 8·0% 
 
versus
 
 75·0 
 
±
 
 12·0%; 
 
P
 
 
 
=
 
 0·022). The GM-CSF mRNA was similar (102·0 
 
±
 
 6·0% 
 
versus
 
89·0 
 
±
 
 5·0%; 
 
P
 
 
 
=
 
 0·475) in both groups. Stimulation of cells with PHA 
 
+
 
 PMA showed no IL-12 expres-
sion but stimulation with lipopolysaccharide induced higher IL-12 mRNA in patients than controls
(83·0 
 
±
 
 14·0% 
 
versus
 
 33·0 
 
±
 
 4·0%; 
 
P
 
 
 
=
 
 0·005). Our data suggest that an inflammatory cytokine signature
exists in TA with a key role for TNF-
 
a
 
, IL-4, IL-10 and IL-12 in different pathological processes of the
disease.
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INTRODUCTION
 
Takayasu’s arteritis (TA) is a chronic granulomatous vasculitis
characterized by stenosis, occlusion or sometimes aneurysm of
large elastic arteries, mainly the aorta and its major branches
including pulmonary and coronary arteries. It is an autoimmune
disease and different cellular and humoral immune mechanisms
are involved in its pathogenesis [1,2].
Granulomatous inflammation, vascular infiltration of mainly
T cells and monocyte/macrophages [3], increased numbers of
HLA-DR
 
+
 
 T cells in the circulation [4] and increased serum lev-
els of interleukin (IL)-6 in TA [5] together suggest a primary
involvement of T cells and monocytes/macrophages in the dis-
ease. The systemic and local production of different cytokines by
these immune effector cells may have a crucial role in mediating
the infiltration of circulating inflammatory cells into the vascular
wall by activating vascular endothelium and in inducing histolog-
ical damage through their direct cytotoxic effect on vasculature
or indirectly by activating cytotoxic effector functions of
recruited inflammatory cells [6–8]. Some of these cytokines, such
as IL-3 and IL-4, also induce proliferation and migration of
smooth muscle cells and/or fibroblasts and thus may be involved
in intimal hyperplasia and fibrosis that lead eventually to steno-
sis or ischaemia of the diseased vessels [9,10]. However, data on
cytokines in TA are very limited and the simultaneous detection
of a wide repertoire of these mediators has not yet been carried
out.
We thus undertook this study to investigate the mRNA
expression of different cytokines including tumour necrosis factor
(TNF)-
 
a
 
, interferon (IFN)-
 
g
 
, IL-2, IL-3, IL-4, IL-10, IL-12 and
granulocyte-macrophage colony-stimulating factor (GM-CSF) in
peripheral blood mononuclear cells (PBMCs) of patients with TA
and healthy controls.
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SUBJECTS AND METHODS
 
Subjects
 
Ten patients with TA (seven females, three males; mean age
26·8 
 
±
 
 9·3 years; range: 18–42 years) and an equal number of age-
and sex-matched healthy controls were enrolled in the study after
obtaining their informed consent. This study was approved by the
Ethics Committee of Sanjay Gandhi Post-Graduate Institute of
Medical Sciences (SGPGIMS), Lucknow, India. All patients
included in the study fulfilled at least three of the classification
and diagnostic criteria of the American College of Rheumatology,
1990 for TA [11] and had an angiographically proven disease.
They were on a maintenance dose of prednisolone (5–10 mg/day)
and azathioprine (2 mg/kg) and their disease was in remission as
per criteria of the disease activity described previously [12]. The
clinical features of the study are given in Table 1.
 
Isolation and activation of PBMCs
 
Fifteen ml of venous blood was obtained from each subject in a
sterile glass tube containing 150 IU of preservative-free heparin
(Sigma, St Louis MO, USA). PBMCs were isolated by the stan-
dard Ficoll-Hypaque (Histopaque, Sigma) density gradient cen-
trifugation method. Their viability as assessed by trypan blue
exclusion test was always 
 
>
 
95%. The preparation of PBMCs was
 
>
 
99% pure and consisted of 65–69% of lymphocytes, 30–35% of
monocytes and 
 
<
 
1% of polymorphs as determined by routine hae-
matological staining of cytospin smears of the cells. One aliquot of
5 
 
¥
 
 10
 
6
 
 cells was used immediately for RNA extraction and the
remaining (usually 
 
≥
 
10 
 
¥
 
 10
 
6
 
) cells were used for activation to
detect constitutive and induced cytokine gene expression,
respectively.
To induce cytokine gene transcription, the cells were stimu-
lated with phytohaemagglutinin (PHA) 
 
+
 
 phorbol 12-myristate
13-acetate (PMA). The combination of PHA and PMA is a potent
stimulus for PBMCs. PHA induces polyclonal activation of T cells
via binding directly to T cell receptors or associated molecules as
well as binding to carbohydrate residues in the glycoprotein of the
cell membrane and PMA acts as an analogue of diacylglycerol
and induces stimulation of lymphocytes and monocytes by acti-
vating the protein kinase signalling pathway [13]. Briefly, the iso-
lated cells were suspended in complete medium consisting of
RPMI-1640 supplemented with 3 m
 
M
 
 of 
 
L
 
-glutamine, 10 m
 
M
 
 of
HEPES buffer, 1 m
 
M
 
 of sodium pyruvate and 10% of heat-
inactivated fetal bovine serum (all from G
 
IBCO
 
 BRL, Grand
Island, NY, USA). A total of 5 
 
¥
 
 10
 
6
 
 cells/well in a final volume of
2 ml of complete medium were dispensed in a six-well tissue cul-
ture plate (Nunclon, Roskilde, Denmark) and incubated for 4 h
under standard tissue culture conditions in the presence of 2 
 
m
 
g/
ml of PHA (Sigma) plus 25 
 
h
 
g/ml of PMA (Sigma). After incu-
bation cells were harvested and used for RNA extraction.
Because lipopolysaccharide (LPS) is a potent stimulator of
monocytic as well as B cells, which are the main producers of IL-
12, and PMA down-regulates the production of this cytokine [14]
in an additional activation protocol, approximately 5 
 
¥
 
 10
 
6
 
PBMCs in a final volume of 1 ml of complete medium were stim-
ulated by incubating with 10 
 
m
 
g/ml of LPS (Sigma) for 12 h, as
described above, to detect IL-12 gene expression in the cells [15].
 
RNA extraction
 
Total cellular RNA from unactivated and activated PBMCs was
extracted by the modified guanidinium thiocyanate–phenol–chlo-
roform method [16]. The RNA pellet obtained was dissolved in
25–50 
 
m
 
l of RNA storage solution (Ambion, Austin, TX, USA)
and stored at 
 
-
 
80
 
∞
 
C until required. Each sample had approxi-
mately 5 
 
m
 
g of total RNA as determined by spectrophotometry.
 
Reverse transcriptase-polymerase chain reaction (RT-PCR)
 
Cytokine gene expression was detected by a single-step RT-PCR
method that includes reverse transcription of mRNA into com-
plementary DNA (cDNA) and its subsequent PCR amplification
by a continuous thermal cycling programme, using the Robust
RT-PCR kit (Finnzymes, OY, Finland) according to the manufac-
turer’s instructions. Briefly, for each RT-PCR reaction 50 
 
h
 
g of
total RNA was mixed to a standard reaction mixture consisting of
1 
 
¥
 
 reaction buffer, 1·5 m
 
M
 
 MgCl
 
2
 
, 200 
 
m
 
M
 
 of each dNTP, 10 pmol
each oligonucleotide primer, 5 units of avian myeloblastosis virus
reverse transcriptase (AMV-RT), 2 units of DyNAzyme EXT
DNA polymerase and diethyl pyrocarbonate (DEPC) (Sigma)-
treated sterile water up to a final volume of 50 
 
m
 
l in a sterile 250 
 
m
 
l
PCR tube (Genei, Bangalore, India). The reaction was carried out
in a DNA thermal cycler (Perkin Elmer Cetus, Norwalk, CT,
USA) and consisted of the following steps: (a) an initial cDNA
synthesis at 48
 
∞
 
C for 45 min followed by inactivation of AMV-RT
and denaturation of cDNA/RNA hybrid at 94
 
∞
 
C for 2 min; (b)
PCR amplification by 35 sequential cycles of denaturation (94
 
∞
 
C
for 45 s), annealing (at cytokine specific temperature for 45 s) and
primer extension (72
 
∞
 
C for 60 s); and (c) a final extension at 72
 
∞
 
C
for 7 min followed by cooling to 12
 
∞
 
C as end of the reaction.
 
Table 1.
 
Clinical features of the study
TA
patient Age/sex
Type of 
disease
ESR
(mm/h)
CRP
(mg/dl) Treatment Disease activity
1. 23/F III 38
 
<
 
0·5 Prednisolone (5 mg/day), azathioprine (2 mg/kg) Inactive
2. 40/F III 22 0·698 Prednisolone (5 mg/day), azathioprine (2 mg/kg) Inactive
3. 20/M III 12
 
<
 
0·5 Prednisolone (10 mg/day), azathioprine (2 mg/kg) Inactive
4. 42/F I 20
 
<
 
0·5 Prednisolone (5 mg/day), azathioprine (2 mg/kg) Inactive
5. 20/F III 11
 
<
 
0·5 Prednisolone (10 mg/day), azathioprine (2 mg/kg) Inactive
6. 18/F III 22 0·25 Prednisolone (10 mg/day), azathioprine (2 mg/kg) Inactive
7. 30/F III 15 0·65 Prednisolone (10 mg/day), azathioprine (2 mg/kg) Inactive
8. 22/M III 25
 
<
 
0·5 Prednisolone (5 mg/day), azathioprine (2 mg/kg) Inactive
9. 35/M III 18
 
<
 
0·5 Prednisolone (5 mg/day), azathioprine (2 mg/kg) Inactive
10. 18/F III 25
 
<
 
0·5 Prednisolone (10 mg/day), azathioprine (2 mg/kg) Inactive
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Amplification of RNA for the housekeeping gene b-actin was
used as the internal quality control. The sequences of the primers
(Quiagen, Hilden, Germany), optimal PCR annealing tempera-
tures (Ta) and size of the amplified PCR product are given in
Table 2. A negative control consisting of a reaction mixture with
no AMV-RT was included in each set of experiments to rule out
amplification of contaminating genomic DNA, if any. A positive
control for each cytokine consisted of RNA derived from
PHA + PMA or LPS-stimulated PBMCs of a healthy individual.
Semiquantification of PCR products
Semiquantification of cytokine gene expression was carried out
by comparing the signal intensities of a cytokine PCR product to
those of b-actin of the same RNA sample using agarose gel elec-
trophoresis followed by densitometric scanning of the amplicon
bands, as described by Walker et al. [17], with some modifications.
Briefly, a 12 ml aliquot of an amplicon was mixed with 2·5 ml of gel
loading dye and electrophoresed through 1·5–1·8% agarose gel
(Sigma) in 0·5¥ TBE buffer (89 mM Tris base, pH 7·6; 89 mM boric
acid and 2 mM EDTA) containing 0·5 mg/ml of ethidium bromide
at 80 V constant voltage field until the dye front had migrated for
a distance of 6 cm (usually 45 min).
The intensities of the product bands were quantified by den-
sitometric scanning of gels using a working station that included a
UV transilluminator lightbox and Kodak CD40 digital camera
with 1D GEL ANALYSIS software connected to a computer. A 100
base pair (bp) DNA ladder molecular marker (MBI, Fermentas,
Lithuana) was run on every gel to confirm the size of the PCR
product.
Statistical analysis
The intensity of a given cytokine and b-actin density in each sam-
ple was compared using the Mann–Whitney U-test. Results were
expressed as mean ± standard deviation (s.d.). A P-value <0·05
was considered to be statistically significant.
RESULTS
Constitutive expression of cytokine genes
There was a constitutive gene expression of TNF-a, IL-3 and IL-
4 but not of the other cytokines studied. The mRNA expression of
TNF-a was significantly higher in patients compared to controls
(69·0 ± 4·0% versus 27·5 ± 18·0%; P = 0·001), that of IL-4 was
present only in patients but not in controls (60·0 ± 10·0% versus
0%; P = 0·001) while that of IL-3 was comparable in both groups
(38·0 ± 6·0% versus 32·0 ± 5·0%; P = 0·651) (Fig. 1a).
Induced expression of cytokine genes
There was significantly increased mRNA gene expression of
TNF-a (127·0 ± 16·0% versus 54·0 ± 6·0%; P = 0·001), IFN-g
(93·0 ± 13·0% versus 57·0 ± 5·0%; P = 0·032), IL-2 (109·0 ± 13·0%
versus 68·0 ± 6·0%; P = 0·015), IL-3 (60·0 ± 8·0% versus
21·2 ± 3·0%; P = 0·045) and IL-4 (68·0 ± 7·0% versus 27·0 ± 7·2%;
P = 0·01) in the PHA + PMA-stimulated PBMCs of the patients
compared to controls. The induced expression of IL-10 in the
patients was significantly lower than controls (35·0 ± 8·0% versus
75·0 ± 12·0%; P = 0·022) and that of GM-CSF was comparable
in  both  groups  (102·0 ± 6·0%  versus  89·0 ± 5·0%;  P = 0·475)
No mRNA expression of IL-12 was detected in PHA + PMA-
stimulated PBMCs. However, stimulation of cells with LPS ind-
uced a significantly increased expression of cytokine mRNA in
patients compared to controls (83·0 ± 14·0% versus 33·0 ± 4·0%;
P = 0·005) (Fig. 1b).
DISCUSSION
The salient findings of our study are the presence of an increased
constitutive mRNA expression of TNF-a and IL-4 and a decrease
in the induced expression of IL-10 mRNA in patients with TA. In
addition, the induced mRNA expression of TNF-a, IFN-g, IL-2,
IL-3, IL-4 and IL-12 was significantly higher in patients compared
to controls while that of GM-CSF was comparable in both groups.
To the best of our knowledge this is the first study detecting simul-
taneously such a large repertoire of cytokines on mRNA or pro-
tein level in TA or other vasculitides.
Some of these cytokines, including TNF-a, IFN-g, IL-2 and
IL-4, have been studied previously in TA but the data available
are very limited. The gene transcripts of TNF-a and IFN-g using
RT-PCR have been demonstrated in the aortic tissues of TA
patients with TA by Seko et al. [18] and support our finding in
the present study of increased mRNA expression of these cytok-
ines. The increased constitutive and induced mRNA expression
of TNF-a in TA PBMCs reported here confirms our recent data
Fig. 1. (a) Bar diagrams showing constitutive cytokine mRNA expression
as percentage of b-actin mRNA in the peripheral blood mononuclear cells
of patients with Takayasu’s arteritis (TA; n = 10) (solid bars) and healthy
controls (HC, n = 10) (hollow bars). (b) Bar diagrams showing induced
cytokine mRNA expression as percentage of b-actin mRNA in the periph-
eral blood mononuclear cells of patients with Takayasu’s arteritis (TA;
n = 10) (solid bars) and healthy controls (HC; n = 10) (hollow bars).
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of increased frequency of TNF-a-positive T cells in patients with
active TA and increased plasma levels of the cytokine in patients
with active and inactive disease (manuscript submitted). The
enhanced gene expression and spontaneous production of TNF-
a by PBMCs [19] as well as elevated serum levels [20,21] and
expression of the cytokine protein in mononuclear cells infiltrat-
ing the arterial wall in other vasculitides [22] corroborates well
with our findings. In contradiction to our previous observation of
normal numbers of IFN-g-positive T cells and normal serum lev-
els of the cytokine (manuscript submitted), in this study we
found an increased induced expression of IFN-g mRNA in the
patients. An important reason for this difference between our
two studies could be the expression of IFN-g by mononuclear
cell populations other than T cells, such as natural killer (NK)
cells and monocyte/macrophages [23]. Similar to our observa-
tion, an increased IFN-g mRNA expression has been reported in
the lesions of giant cell arteritis (GCA) [24] and in the lesions as
well as PBMCs of patients with Wegener’s granulomatosis (WG)
[25].
The data available on IL-2 in TA is contradictory. Using a bio-
assay, Alcocer-Varela et al. [26] have shown a decrease in produc-
tion of IL-2 by PHA-stimulated T cells in active TA. However,
Sharma et al. [27], using a similar method, reported an increased
production of IL-2 by T cells in the disease. Similarly, the
increased IL-2 gene expression TA PBMCs reported here does
not corroborate our previous data of a lower frequency of IL-2-
producing T cells and a decrease in plasma levels of the cytokine
in active TA (manuscript submitted). In the present study all the
patients were on immunosuppressive therapy and were in remis-
sion; however, in the previous study, although numbers of IL-2-
producing T cells and plasma levels of the cytokine were low in
active TA, inactive patients had IL-2-positive T cells and plasma
levels of the cytokine comparable to controls. The increased IL-2
mRNA expression in patients with inactive disease reported here
might be due to differences in stimulation protocol and/or sensi-
tivity of the techniques used.
There has been only a single previous study on IL-4 in TA by
Sharma et al. [27]. Using a bioassay, these authors have shown
normal production of IL-4 by PHA-stimulated purified T cells of
patients with TA. Our results, including a constitutive mRNA
expression of IL-4 in patients but not in controls and its increased
expression in PHA + PMA-stimulated TA PBMC compared to
controls, do not support this study. An important reason for the
failure to detect increased T cell production of IL-4 by Sharma
et al. [27] may be the low sensitivity of the bioassay compared to
RT-PCR and/or loss of IL-4-producing T cell subsets during the T
cell purification procedure. Previous reports of different vasculo-
pathies, including circulating levels of IL-4 in Kawasaki disease
[28], IL-4 mRNA expression by peripheral blood T cells as well as
by T cell clones derived from diseased tissue in WG [25] and the
increased expression of the cytokine mRNA by PBMCs as well as
plasma levels of the cytokine in scleroderma, a microvascular
fibrotic disease [29], are consistent with our findings of IL-4 in TA.
Other cytokines, including IL-3, IL-10, IL-12 and GM-CSF,
either at mRNA or protein levels have not been studied previ-
ously in TA. We have observed increased expression of IL-3
mRNA occurring only after induction in the patients. Among
inflammatory vasculopathies, increased IL-3 gene expression has
been demonstrated previously in T cells infiltrating the athero-
sclerotic lesions [7] and our present study constitutes the first
report suggesting the role of IL-3 in a vasculitic entity. We also
studied GM-CSF, but its expression was not different to controls.
The IL-10 mRNA was not detected under constitutive conditions
and the stimulated cells of the patients exhibited low expression
compared to controls. Low IL-10 mRNA expression has been
reported in arterial lesions with no giant cells compared to those
with giant cells in patients with GCA [24]. Similar to our obser-
vation, the PBMCs of localized WG have low IL-10 mRNA levels
Table 2. Oligonucleotide primers and related information
Target
gene
Primer sequence: 
Forward: 5¢-3¢ (bp numbering)
Reverse: 5¢-3¢ (bp numbering) Accession no. Ta* (∞C)
Product 
size (bp)
TNF-a GAGTGACAAGCCTGTAGCCCATGTTGTAGC (337–366) M10988 66 444
GCAATGATCCCAAAGTAGACCTGCCCAGACT (750–780)
IFN-g TCTGCATCGTTTTGGGTTCTC (35–55) AY255837 55 321
TCAGCTTTTCGAAGTCATCTC (335–355)
IL-2 ATGTACAGGATGCAACTCCTGTCTT (19–43) BC066254 55 457
GTCAGTGTTGAGATGATGCTTTGAC (452–476)
IL-3 TCCAAACATGAGCCGCCTGCC (40–60) BC066276 60 211
CATCAGAATGTCTTGGTCTTC (230–250)
IL-4 CCTCTGTTCTTCCTGCTAGCA (93–113) BC067515 58 300
GCCGTTTCAGGAATCGGATCA (373–393)
IL-10 ACAGCTCACCACTGCTCTGT (64–83) NM000572 60 327
AGTTCACATGCGCCTTGATG (371–390)
IL-12p40 AGTGTCAAAAGCAGCAGAGG (505–524) NM002187 60 363
AACGCAGAATGTCAGGGAG (849–867)
GM-CSF GAGCATGTGAATGCCATCCAGGAG (99–122) M10663 60 390
CTCCTGGACTGGCTCCCAGCAGTCAAA (414–440)
b-Actin CACTCTTCCAGCCTTCCTTCC (852–872) NM001101 62 311
CGGACTCGTCATACTCCTGCTT (1148–1169)
*Ta = annealing temperature of primers.
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compared to healthy controls and a reciprocal relationship exists
between IL-10 and IL-4 mRNA expression in these patients [25].
This study in WG suggests that the low IL-10 mRNA expression
observed by us in TA could be due to an increased constitutive
and induced transcription of IL-4 in the patients.
We did not detect IL-12 mRNA in PHA + PMA-stimulated
PBMCs in TA, but LPS stimulation of the cells induced signifi-
cantly increased mRNA expression in patients compared to con-
trols. Increased expression of IL-12 in arterial lesions in GCA [24]
and increased intracellular and extracellular production of the
cytokine by monocytes in WG [30,31] support our findings of
increased IL-12 in TA. The elevated mRNA levels of different
inflammatory cytokines observed in the present study further sup-
port increased transcription of IL-12 in the disease. We did not
observe an increased constitutive mRNA expression of most of
the cytokines, including IL-12, because all our patients were
under immunosuppressive therapy and their disease was in remis-
sion. It is probable that, like TNF-a and IL-4, more cytokines may
have a constitutive expression in untreated patients with active
TA.
According to the classical Th1 : Th2 paradigm [32], most
cytokines, such as TNF-a, IFN-g, IL-2, IL-3 and IL-12 that have
been observed to have increased mRNA expression in the present
study, are Th1-type. IL-4, which is viewed generally as a Th2
cytokine, has also been shown recently to promote the production
of a Th1 cytokine such as IFN-g in the presence of IL-2 and IL-12
and induce cellular immunity [33]. Thus increased expression of
all these cytokines and reduced expression of IL-10, which is a
major Th2 cytokine, together suggest that a Th1-type cytokine
profile exists in patients with TA.
The presence of constitutive transcripts of TNF-a and IL-4 in
TA PBMCs is one of the important findings of this study. TNF-a,
along with IFN-g, is reported to have multiple activating and cyto-
toxic effects on vasculature. They activate endothelial cells to
express adhesion molecules and chemokines that direct circulat-
ing leucocytes into the vessel wall. In addition, local production of
these cytokines by the infiltrating cells are potent mediators of
granulomatous inflammation and may cause vascular damage
either directly or by priming the vascular tissues for T cell-
mediated injury [34–36]. Different pathological findings in TA,
including granulomatous inflammation, increased expression of
intercellular adhesion molecule-1 and MHC-I and MHC-II mol-
ecules in the lesion, validate the role of these cytokines in the
disease [2]. Furthermore, cytokines such as TNF-a, IFN-g, IL-4
and  IL-12  also  promote  humoral  immunity  [37]  and  together
are responsible for the generation of different autoantibodies
observed in TA [2,12]. Although IL-4 is considered generally to be
an anti-inflammatory cytokine, recent reports suggest that it may
be an important inflammatory cytokine in vasculitides. It syner-
gizes with TNF-a in inducing expression of vascular cell adhesion
molecule-1 on endothelial cells and causes apoptosis through the
caspase-3-dependent pathway [38] and induces Fas-ligand-
mediated cytotoxic activity of T cells [39]. IL-4 is also a potent
profibrogenic cytokine [40] and may have a role in vessel occ-
lusion, which occurs during the chronic stage of the disease.
Another important finding of our study is the expression of
low IL-10 and high IL-12 mRNA in stimulated PBMCs of the
patients and may have important implications in TA. IL-10 is a
potent anti-inflammatory cytokine that maintains peripheral tol-
erance by reducing antigen presentation, inhibiting cytokine pro-
duction by T cells and monocytes/macrophages and executing
apoptosis of antigen-activated T cells [41]. However, IL-12 pro-
motes inflammation by inducing inflammatory cytokine produc-
tion by T cells and monocyte/macrophages [42]. Thus, low IL-10
and high IlL-12 mRNA expression in the patients may constitute
a crucial factor responsible for the persistence of circulating acti-
vated T cells and chronic inflammation in TA.
In conclusion, we have demonstrated an increased constitu-
tive expression of TNF-a and IL-4 mRNA as well as increased
induced expression of TNF-a, IFN-g, IL-2, IL-3, IL-4 and IL-12
mRNA but an impaired induction of IL-10 mRNA in patients
with TA, suggesting an important role of these cytokines in dif-
ferent pathological processes and immune dysfunction in the dis-
ease. Further studies focusing on trigger(s) that induce such a
cytokine profile and molecular characterization of the cells pro-
ducing TNF-a, IL-4 and IL-10 may provide new insights into the
immunopathogenesis of TA and lead to the development of spe-
cific biological therapy for the disease.
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